DCGI approves use of AstraZeneca’s drug for patients with high-risk early breast cancer

DCGI approves use of AstraZeneca’s drug for patients with high-risk early breast cancer


AstraZeneca India, a biopharmaceutical company, on Friday said that it had received the Drugs Controller General of India (DCGI) approval to market its drug Lynparza (Olaparib) as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high-risk early breast cancer.

The use will be restricted to patients who have previously been treated with neoadjuvant or adjuvant chemotherapy. It is also approved for use in the United States, European Union, Japan, and other countries.

“We are constantly pushing the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer. The regulatory approval of Lynparza, the first and only drug targeting BRCA mutations in early breast cancer, reinforces our growing capabilities in innovation and clinical research for providing holistic solutions for cancer treatment in India,” said Gagandeep Singh, Managing Director and Country President, AstraZeneca India.

Meaningful improvement

The approval was based on results from the OlympiA Phase III trial, which suggested that Olaparib demonstrated a statistically significant and clinically meaningful improvement, with an overall survival benefit.

Dr. Anil Kukreja, Vice President, Medical Affairs and Regulatory, AstraZeneca India, said, “The new data from the OlympiA Phase III trial also confirms that it significantly extends the lives of the patients. The approval will provide oncologists with a potential therapeutic option to be given with curative intent to eligible early breast cancer patients.” 

Published on

August 20, 2022



Source link

Bionic hand can be updated with new gestures, anytime, anywhere

Bionic hand can be updated with new gestures, anytime, anywhere


ReutersAustralian swimmer Jessica Smith has had an uneasy relationship with prosthetics since a childhood accident, but her convictions are being challenged by a British bionic hand that can be updated remotely anywhere in the world.

The 2004 Athens Paralympian was born without a left hand.

Her parents were advised to fit a prosthesis to help with her development, but the device caused her to upset a boiling kettle when she was a toddler, causing burns to 15 per cent of her body.

“There’s always been an association between the fact this prosthetic aid didn’t actually help, it created the most traumatic event in my life,” she said.

But her curiosity was sparked when she was approached by COVVI, based in Leeds, northern England, to try its Nexus hand.

Knowing it would be an emotional challenge, Smith was fitted with the device in April at the age of 37. “I think that I was ready to try something like this,” she said.

Bionic hands convert electrical impulses from the muscles in the upper arm into movement powered by motors in the hand, enabling a user to hold a glass, open a door or pick up an egg.

Simon Pollard, who founded COVVI five years ago, said he wanted to add bluetooth to the device to allow the company’s specialists to update it via an app.

“The fact we can change some of the things that the customer wants remotely is a really powerful thing and a first to market,” the chief executive said.

Some rival bionic hands can be app-controlled, but Pollard said the ability to talk to a single device set the Nexus apart.

To do that anonymised data is collected for every user, a task managed by partner NetApp.

Pollard said COVVI had signed up 27 distributors globally, including in Australia, China and the United States, and he aimed to increase monthly production to 100.

Smith, who is a speaker and children’s author, said COVVI was already creating new movements for her.

“I’ve had a few kids ask if I can do different hand gestures, some polite some not so polite,” she said. “I asked COVVI this morning, and I know that will be done in the next couple of hours.”

She said the tech was not just changing her life, it was changing the lives of her three children.

“They think it’s amazing and I’m like half human-half robot,” she said.

She said the “bionic” appearance of the hand was an attraction, given her pride in difference.

“I’m not trying to hide who I am,” she said. “I’m adding and expanding on who I am by being able to access technology that’s never been available before.”

Published on

August 16, 2022



Source link

Zombie crew: How dead spiders returned as robots

Zombie crew: How dead spiders returned as robots


The Spiderman has done a lot of impossible things on the silver screen; now scientists are putting the arachnids that inspired the superhero to funny uses.

Te Faye Yap, a mechanical engineer at Rice University, Houston, noticed that dead spiders always have their legs curled in, and wondered why. She took one up for detailed study and discovered that a spider moves its legs through hydraulic pressure — a chamber in its body pumps air into tubes in its legs, which then stretch out; when air is drawn back, the legs curl in.

Intrigued by this, Yap and her colleague Daniel Preston collected more dead spiders to experiment on.

They stuck a syringe into the spider’s chamber and pushed in air gently — the legs came alive, stretching out. Now you have made yourself a robotic arm that can grip and pick up really tiny objects without damaging them.

The dead spiders can pick up more than 130 per cent of their body weight and last through 1,000 open-close cycles, researchers Yap, Zhen Liu, Anoop Rajappan, Trevor Shimokusu and Preston say in a paper published in Advanced Science. They call the use of biotic materials as robotic components “necrobotics”. Giving the animals a coat of beeswax can slow the loss of body weight. Such “necrobotic grippers” could have multiple applications, including assembling things like microelectronics and for collecting specimens, they say.





Source link

World’s first “synthetic embryo”: why this research is more important than you think

World’s first “synthetic embryo”: why this research is more important than you think


In what’s reported as a world-first achievement, biologists have grown mouse embryo models in the lab without the need for fertilised eggs, embryos, or even a mouse – using only stem cells and a special incubator.

This achievement, published in the journal Cell by a team led by researchers from the Weizmann Institute of Science in Israel, is a very sophisticated model of what happens during early mouse embryo development – in the stage just after implantation.

This is a crucial stage: in humans, many pregnancies are lost around this stage.

Having models provide better understanding to study what can go wrong, and possibly insights into what we may be able to do about it.

The tiniest cluster not only does mimic the cell specification and layout of an early-stage body plan – including precursors of heart, blood, brain and other organs – but also the “support” cells like those found in the placenta and other tissues required to establish and maintain a pregnancy.

The earliest stages of pregnancy are difficult to study in most animals. The embryos are microscopic, tiny clusters of cells, difficult to locate and observe within the uterus.

But we do know that at this stage of development, things can go awry; for example, environmental factors can influence and interfere with development, or cells fail to receive the right signals to fully form the spinal cord, such as in spina bifida. Using models like this, we can start to ask why.

However, even though these models are a powerful research tool, it is important to understand they are not embryos.

They replicate only some aspects of development, but not fully reproduce the cellular architecture and developmental potential of embryos derived after fertilisation of eggs by sperm – so-called natural embryos.

The team behind this work emphasises that they were unable to develop these models beyond eight days, while a normal mouse pregnancy is 20 days long.

Are ‘synthetic embryos’ of humans on the horizon?

The field of embryo modelling is progressing rapidly, with new advances emerging every year.

In 2021, several teams managed to get human pluripotent stem cells (cells that can turn into any other type of cell) to self-aggregate in a Petri dish, mimicking the “blastocyst”.

This is the earliest stage of embryonic development just before the complex process of implantation, when a mass of cells attach to the wall of the uterus.

Researchers using these human embryo models, often called blastoids, have even been able to start to explore implantation in a dish, but this process is much more challenging in humans than it is in mice.

Growing human embryo models of the same complexity that has now been achieved with a mouse model remains a distant proposition, but one we should still consider.

Importantly, we need to be aware of how representative such a model would be; a so-called synthetic embryo in a Petri dish will have its limitations on what it can teach us about human development, and we need to be conscious of that.

An important consideration is whether using cells for this particular type of research – trying to mimic an embryo in a dish – requires any specific consent.

However, it is important to recognise that there are existing laws and international stem cell research guidelines that provide a framework to regulate this area of research.

In Australia, research involving human stem cell embryo models would require licensing, similar to that required for the use of natural human embryos under law that has been in place since 2002.

However, unlike other jurisdictions, Australian law also dictates how long researchers can grow human embryo models, a restriction that some researchers would like to see changed.

There is a distinction between banning the use of this technology and technologies like cloning in humans for reproductive use, and allowing research using embryo models to advance our understanding of human development and developmental disorders that we can’t answer by any other means.

The science is rapidly advancing. While mostly in mice at this stage, now is the time to discuss what this means for humans, and consider where and how we draw the line in the sand as the science evolves.

By Megan Munsie, Professor Emerging Technologies (Stem Cells), The University of Melbourne

Published on

August 07, 2022



Source link

ISRO’s maiden SSLV carrying earth observation & student satellite lifts off from Sriharikota

ISRO’s maiden SSLV carrying earth observation & student satellite lifts off from Sriharikota


ISRO’s maiden small satellite launch vehicle (SSLV), carrying earth observation satellite EOS-02 and co-passenger students satellite AzaadiSAT lifted off from this spaceport on Sunday. The SSLV-D1/EOS-02 mission by the Indian space agency is aimed at garnering a larger pie in the small launch vehicles market, as it can place the satellites into Low Earth Orbit.

“The SSLV can put payloads (mini, micro or nanosatellites) weighing up to 500 kg into the 500 km planar orbit,” the Indian Space Research Organisation (ISRO) said. At the end of a seven-and-a-half-hour countdown, the 34-metre-long SSLV soared majestically at 9.18 am amid cloudy skies to place the satellites into the intended orbit.

The EOS-02 is an experimental optical remote sensing satellite with a high spatial resolution. EOS-02 belongs to the microsatellite series of space crafts. The AzaadiSAT is an 8U Cubesat weighing around 8kgs. Girl students from rural regions across the country were guided to build these payloads.

The payloads are integrated by the student team of Space Kidz India. “The ground system developed by ‘Space Kidz India’ will be utilised for receiving the data from this satellite,” ISRO said.

Published on

August 07, 2022





Source link

India to enhance lab capacities for monkeypox testing

India to enhance lab capacities for monkeypox testing


The Union Ministry of Health and Family Welfare plans to convert 17 integrated disease surveillance programme laboratories across some States, as additional monkey pox testing labs. The conversion and upgrade of the labs are expected over the next seven days, senior officials told BusinessLine.

The move is expected to help in quicker testing of suspected monkeypox virus samples and hasten detection of cases.

The need to increase lab count had come up for discussion during the high-level meeting called by the Directorate General of Health Services (DGHS) on Sunday.

“Some minor modifications are required in these IDSP labs. So in a week or seven-days’ time, the labs should be ready for testing of monkeypox viruses. The addition of the new labs will facilitate early detection and prevention,” the official said.

At present, there are 15 ICMR trained research and diagnostic laboratories in the country.

“To help the country’s preparedness for monkeypox detection, 15 virus research and diagnostic laboratories across the country, which are geographically well distributed and strategically located have already been trained in the diagnostic test by ICMR – NIV Pune,” the ICMR said in a tweet .

India has so far reported four confirmed cases of monkeypox, while samples have been sent for testing in the case of a suspected fifth case from Telangana. “We are awaiting reports,” the Health Ministry official said adding that the condition of the four patients – three from Kerala and one from New Delhi – are stable and “they are recovering well”.

In the current global outbreak, over 16,000 cases have been reported across 70-odd countries so far, and the number of confirmed infections rose 77 per cent from late June through early July, as per WHO data.

The WHO had earlier declared it as a public health emergency of international concern.

Stepping up surveillance

According to the Ministry official, guidelines have been issued to State governments to “step up surveillance” and continue on the tracking, testing and treatment and isolation protocols of monkeypox cases. These also include monitoring the close contacts of the patients.

“ The Centre will also help and step in where necessary. We had sent teams to Kerala too,” he said.

Satish Koul, Director, Internal Medicine, Fortis Memorial Research Institute, said the virus spreads by close contact, skin-to-skin contact and droplet infection. “Being a viral disease the total duration is around three to four weeks. As of now, prevention is better than cure,” he said.

Covid cases

Meanwhile, India reported 16,866 Covid cases,on a 24-hour basis. Daily cases came down in comparison to the 20,200 infections reported a day-before (July 24). However, the country’s daily positivity rate was at 7.03 per cent, after nearly 170 days; while the weekly positivity rate was at 4.43 per cent.

Active cases decreased by 1,323, and they account for 0.34 per cent of the total infections in the country. Recovery rate was 98.46 per cent, data from the Ministry said.

Published on

July 25, 2022



Source link

YouTube
Instagram
WhatsApp